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Abstract
Background: Ovarian carcinomas from 30 BRCA1 germ-line carriers of two distinct high penetrant founder
mutations, 20 carrying the 1675delA and 10 the 1135insA, and 100 sporadic cases were characterized for somatic
mutations in the TP53 gene. We analyzed differences in relation to BRCA1 germline status, TP53 status, survival
and age at diagnosis, as previous studies have not been conclusive.
Methods: DNA was extracted from paraffin embedded formalin fixed tissues for the familial cases, and from
fresh frozen specimen from the sporadic cases. All cases were treated at our hospital according to protocol.
Mutation analyses of exon 2 – 11 were performed using TTGE, followed by sequencing.
Results: Survival rates for BRCA1-familial cases with TP53 mutations were not significantly lower than for familial
cases without TP53 mutations (p = 0.25, RR = 1.64, 95% CI [0.71–3.78]). Median age at diagnosis for sporadic (59
years) and familial (49 years) cases differed significantly (p < 0.001) with or without TP53 mutations. Age at
diagnosis between the two types of familial carriers were not significantly different, with median age of 47 for
1675delA and 52.5 for 1135insA carriers (p = 0.245). For cases ≥50 years at diagnosis, a trend toward longer
survival for sporadic over familial cases was observed (p = 0.08). The opposite trend was observed for cases <50
years at diagnosis.
Conclusion: There do not seem to be a protective advantage for familial BRCA1 carriers without TP53 mutations
over familial cases with TP53 mutations. However, there seem to be a trend towards initial advantage in survival
for familial cases compared to sporadic cases diagnosed before the age of 50 both with and without TP53
mutations. However, this trend diminishes over time and for cases diagnosed ≥50 years the sporadic cases show
a trend towards an advantage in survival over familial cases. Although this data set is small, if confirmed, this may
be a link in the evidence that the differences in ovarian cancer survival reported, are not due to the type of BRCA1
mutation, but may be secondary to genetic factors shared. This may have clinical implications for follow-up such
as prophylactic surgery within carriers of the two most frequent Norwegian BRCA1 founder mutations.
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Ovarian cancer is one of the leading causes of cancer-
related death in women today. It is the 4th most common
cancer in women in Norway and accounts for 5 – 6% of
all cancers [1,2]. Mean age at diagnosis for sporadic cases
have been reported to 62.3 years [3], and in Norway to 65
years. Age-standardized incidence rates were 13.5 pr
100.000, and close to 40% of the patients is achieving 5-
year survival according to The Norwegian Cancer Registry
(OVANOR 1991 – 1996).
Almost 10% of epithelial ovarian cancer cases are associ-
ated with dominant genetic predisposition, in most cases
(80 – 90%), linked to mutations in BRCA1 or BRCA2 [4-
6]. Mean age at diagnosis for these inherited cases have
been reported to be from 49 to 54.3 years [3,7]. The pen-
etrance of the disease in mutation carriers varies, and has
been reported to be from 27 – 80% [8-10]. It should be
noted that both the incidence rate for hereditary cases and
the penetrance of the disease may differ depending on
geographic and ethnic origin [11]. The survival rate may
also vary depending on type and localization of the muta-
tion. Some studies have reported that ovarian cancer
patients carrying germ-line BRCA1 mutations have an
enhanced survival rate compared to sporadic cases [3,12-
14]. Other studies demonstrated only an initial survival
advantage that disappeared with time, and concluded that
no enhanced survival rates follows BRCA1 dysfunction
[15-17]. These studies predict a survival rate for BRCA1
familial ovarian cancer that is equal to or higher than non-
familial cases.
Both the penetrance estimates and the survival rates are
based on studies in populations with strong founder
effects, and may therefore be biased. The type of mutation
in the BRCA1 gene may affect the timing of the diagnosis
of the disease, the response to environmental exposure
causing DNA damage, the efficiency of DNA repair, and
the frequency of somatic mutations developing in the
tumor. These factors may in turn affect the survival rate.
Mutations in the TP53 tumor suppressor gene are the
most common genetic alteration in human tumors and
have been suggested as a molecular marker for prognosis.
TP53 encodes a nuclear phosphoprotein located at chro-
mosome region 17p13 involved in cell cycle arrest and
DNA repair and somatic TP53 mutations are known to
associate with familial ovarian cancer. In ovarian tumors
from BRCA1 mutation carriers, somatic TP53 mutations
are found in 60 – 80% of the cases [18-22]. Thirty to 50%
of all ovarian cancers have been reported to harbor a TP53
mutation [18-20,23,24]. Further, in 30 – 85% of the spo-
radic ovarian carcinomas both a TP53 mutations and a
somatic BRCA1/BRCA2 mutation have been found
[18,20,25].
These findings implicate that TP53 and BRCA1 directly
interacts and may play an important role in DNA repair
processes and tumor suppression [26,27]. However,
despite the high frequency of mutations in the tumor sup-
pressor gene TP53, there are several reports concluding
that TP53 is not a good predictor of prognosis in sporadic
ovarian cancer patients [24,28,29].
We have previously reported two Norwegian BRCA1
founder mutations; 1135insA [30] and 1675delA [11].
Carriers of these mutations show almost the same pene-
trance for ovarian- and breast cancer and the penetrance is
also high compared to most reported BRCA1 mutation
carriers. By age 50, 48% of mutation carriers had experi-
enced breast- and/or ovarian cancer. Mean age of ovarian
cancer diagnosis was ~55 years [10]. Three per cent of all
Norwegian ovarian cancers are caused by either of the two
founder mutations [31]. As a result of a clinical follow-up
program for early diagnosis in women from breast-ovar-
ian cancer kindreds, these two mutations may account for
more than half of those with a BRCA1 mutation in Nor-
way. The histopathological characteristics of both breast
and ovarian cancer indicated an unfavorable prognosis in
these mutation carriers [32].
In the present study, we have screened epithelial ovarian
tumors from 30 familial cases and 100 sporadic cases for
somatic mutations in the TP53 gene. The cancer treatment
was according to our hospital protocol. The familial cases
consisted of one group with the BRCA1 1135insA muta-
tion and the other had the BRCA1 1675delA mutation
[10]. The TP53 mutation status was correlated to survival,
age at diagnosis and histopathological features.
Materials
Formalin fixed and paraffin embedded ovarian cancer tis-
sue from 30 BRCA1 germ line mutation carriers were col-
lected and used for DNA extraction. Of the familial cases
20 patients carried the 1675delA mutation and another
10 patients the 1135insA mutation, which is a representa-
tive distribution between the two mutations in the Nor-
wegian population. The BRCA1 carriers were from
families with at least two first-degree relatives, or second-
degree relatives through male, with ovarian cancer and/or
breast cancer under age 60. All cases were sampled from
pedigree regardless of survival status, as ovarian cancer
treatment is centralized to our hospital. Analysis of fresh
frozen specimen of tumor DNA from the 100 sporadic
cases sampled from 1992–2003, included in this study
has previously been reported [29]. Both groups were diag-
nosed and treated at the Norwegian Radium Hospital
according to protocol. The patient characteristics are
shown in Table 1. All tumors were reviewed at our depart-
ment of pathology, the familial tumors by our team
pathologist, and were classified and graded according toPage 2 of 8
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up time for each case was calculated from the date of diag-
nosis up to date of death or end of study (15th April,
2004).
Methods
DNA extraction and TP53 mutation analysis
DNA was manually extracted from paraffin-embedded tis-
sue sections of tumor material using 5 sections of 10 µ. A
modification of the procedure described by Miller [33]
was used. The modification included using as much as
possible of the top water layer of the 700 ml DNA/lysis
buffer and 1 ml phenol/chloroform/water mix, and
repeating the extraction step once. The protocol was opti-
mized to give high yield of good quality DNA.
Mutation analyses of exons 2–11 of the TP53 gene in the
30 cases with BRCA1 germ line mutations were performed
by TTGE followed by sequencing. Primers, PCR condi-
tions and gel running conditions were as described else-
where [34]. Samples with aberrantly migrating bands on
TTGE were isolated, submitted to a new PCR and
sequenced. Analysis of the fresh frozen specimen of tumor
DNA from the 100 sporadic cases has previously been
reported [29].
Statistical analyses
In univariate analyses, a log rank test have been used to
investigate the effect of age at diagnosis, BRCA1 and TP53
mutations on the survival rate. In multivariate analyses,
Cox proportional hazards regression analysis was used.
Hazard ratios (HR's) are given with 95% confidence inter-
vals (CI's). Statistical significance rates were set at 0.05.
The software SAS® version 8.2 was used for statistical
analyses.
Results
TP53 characterizations and novel mutations
Nineteen of the 30 ovarian carcinomas showed one or
more aberrant migrating bands on TTGE in one or more
exons and was sequenced (Table 2). A total of 21 sequence
changes were detected. Two cases had two different TP53
sequence changes in their tumors, one being a silent
mutation. Nine mutations were missense mutations, four
Table 1: Patient characteristics
Sporadic cases BRCA1 carriers
All familial cases 1135insA 1675delA
No of cases 100 30 10 20
Age at diagnosis: Median 59 49 52.5 47
range 39 – 80 39 – 80 41 – 80 39 – 65
FIGO stage
I – II 9 (9.0%) 8 (26.7%) 2 (20.0%) 6 (30.0%)
III 65 (65.0%) 14 (46.7%) 5 (50.0%) 9 (45.0%)
IV 26 (26.0%) 8 (26.7%) 3 (30.0%) 5 (25.0%)
Histology
Serous 82 (82.0%) 24 (80.0%) 7 (70.0%) 17 (85.0%)
Mixed 7 (7.0%) 2 (6.6%) 1 (10.0%) 1 (5.0%)
Endometroid 5 (5.0%) 3 (10.0%) 1 (10.0%) 2 (10.0%)
Unclassified 6 (6.0%) 1 (3.3%) 1 (10.0%) 0
Grade of differentiation
1 7 (7.0%) 0 0 0
2 26 (26.0%) 5 (16.6%) 1 (10.0%) 4 (20.0%)
3 67 (67.0%) 24 (80.0%) 9 (90.0%) 15 (75.0%)
Unknown 0 1 (3.3%) 0 1 (5.0%)
Survival >5 years 23 (23.0%) 10 (33.3%) 3 (30.0%) 7 (35.0%)
TP53 mutation status 72.0% 53.3% 50.0% 55.0%
All tumors are epithelial adenocarcinomasPage 3 of 8
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ously reported as polymorphisms) and two were intronic
sequence changes of unknown function.
The frequency of transitions vs. transversion in this hered-
itary cohort (85.7% and 14.3%) was also quite similar to
that reported in the IARC database for sporadic cases
(88% and 12%), but differed slightly from the sporadic
cases in this study (76.4% and 23.6%). The frequency of
mutations likely to cause protein alteration were 68.0%
(68/100) for the sporadic cases and 53.3%(16/30) for the
familial cases. The TP53 mutation frequency in the two
different BRCA1 carriers differed slightly with 11/20
(55.0%) in the BRCA1 1675delA carriers and 5/10
(50.0%) in the BRCA1 1135insA carriers. The 1675delA
carriers had 7.7% transversions and 92.3% transitions
while the 1135insA carriers had 12.5% transversion and
82.5% transitions. Four of the TP53 mutations were novel
and not previously reported in ovarian cancer in the IARC
TP53 Database [35] or the SOUSSI database. These muta-
tions affected codon 205 (tyr>ser), 260 (ser>ser), 267
(arg>gln) and 293 (gly>arg). All mutations detected
resided in exons 5–8. When comparing the TP53 muta-
tion spectrum in these familial cases with that of ovarian
cancers cases reported in the IARC database and to the 100
sporadic ovarian cancer cases with a TP53 mutation, no
obvious differences were seen either with respect to exon
distribution or codon wise (data not shown), although a
slightly lower frequency of mutations in exon 5 and a
slightly higher in exon 8 were seen in the hereditary cases.
The TP53 mutations in the 100 sporadic cases used in this
study is reported elsewhere [29].
Age at diagnosis, survival, BRCA1 and TP53 status
Median age at diagnosis among sporadic cases and famil-
ial cases that carried 1675delA or 1135insA mutations is
presented in Table 1. As expected, the familial cases are
diagnosed earlier in life than sporadic cases (p < 0.001).
Table 2: TP53 mutations, survival and histopathological features for each case.
Case aBRCA1 
carrier type
Stage bGrade Type TTGE Exon Codon Mutation aa change Age of 
diagnosis
cSurvival 
months
dVital 
status
3453 1 3 2 ser pos 5 559+1G>A splice 53 83 1
10 1 3 3 ser pos 6 213 CGA>TGA arg>stop 65 22 3
2857 1 3 3 ser pos 6 213 CGA>TGA arg>stop 53 83 3
4 1 4 3 ser pos 6 216 GTG>ATG val>met 59 11 3
27 1 2 3 endo pos 7 237 ATG>ATA met>ile 39 61 3
8e 1 3 3 ser pos 7 260 TCC>TCT ser>ser 49 84 3
8 306 CGA>TGA arg>stop
14 1 1 3 ser pos 8 267 CGG>CAG arg>gln 51 25 3
13 1 4 3 ser pos 8 273 CGT>AGT arg>ser 39 15 3
29 1 3 3 mix pos 8 273 CGT>TGT arg>cys 50 36 3
2842 1 1 4 3 ser pos 8 273 CGT>TGT arg>cys 39 35 3
21 1 3 3 ser pos 8 293 GGG>AGG gly>arg 39 21 3
26 1 3 2 ser pos intron G>A ivs5 53 93 1
9 1 4 2 ser neg 50 39 3
11 1 3 3 ser neg 44 8 3
17 1 3 3 ser neg 47 30 3
24 1 2 4 ser neg 59 20 3
34 1 1 3 ser neg 46 120 1
30 1 1 2 ser neg 43 199 2
32 1 2 3 ser neg 48 108 1
3351 1 4 3 endo neg 44 9 3
1 2 4 3 ser pos 5 144 CAG>TAG gln>stop 41 1 3
3 2 3 3 uncl pos 6 196 CGA>TGA arg>stop 48 46 3
20 2 3 3 ser pos 6 205 TAT>TCT tyr>ser 52 36 3
28 2 4 3 ser pos 7 261 AGG>AGA arg>arg 80 12 3
7e 2 3 3 ser pos 7 255 ATC>GTC ile>val 58 30 3
5 141 TGC>TGT cys>cys
12 2 1 3 ser pos 8 280 AGA>GGA arg>gly 49 134 1
15 2 3 3 ser pos intron C>T ivs7 50 19 3
5 2 4 3 ser neg 60 45 3
18 2 2 3 endo neg 44 117 3
22 2 3 2 mix neg 47 96 3
a: 1 = 1675delA and 2 = 1135insA. b: undifferentiated (4). c: all patients were followed until diseased or to 15th April, 2004. d: alive without cancer 
(1), alive with cancer (2), and dead by cancer (3). e: two different mutations detected in sample.Page 4 of 8
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1135insA and 1675delA mutation carriers was not signif-
icant (p = 0.245).
In the univariate analysis of the combined group, neither
BRCA1 status nor age at diagnosis was significantly asso-
ciated to survival (p = 0.87 and p = 0.50 for BRCA1 status
and age at diagnosis (categorized into < 50 and ≥ 50
years), respectively). TP53 mutation did not significantly
reduce the survival rates (p = 0.35). Notably, interaction
between BRCA1 status and TP53 status was borderline sig-
nificant (test for interaction: p = 0.06) while the one
between BRCA1 status and age at diagnosis was statisti-
cally significant (test for interaction: p = 0.05). We further
analyzed these factors adjusted for tumor grade, however,
results did not substantially change (test interaction: p =
0.04 and p = 0.05 for BRCA1*TP53 and BRCA1*age at
diagnosis, respectively).
No association between age at diagnosis and survival time
was found among sporadic cases (p = 0.88). Familial cases
with late age at diagnosis (≥50 years) had a slightly higher
risk of dying than the cases with an early age at diagnosis,
however the association did not reach significance, possi-
bly due to a lack of statistical power (RR = 1.65, 95% CI
[0.79–3.43], p = 0.14). Among cases diagnosed at age 50
years or more, familial cases had a trend towards a higher
risk of dying than sporadic cases (RR = 1.75, 95% CI
[0.93–3.30], p = 0.08). After adjustment for the effect of
tumor grade and TP53 status (RR = 1.80, 95% CI [0.94–
3.43], p = 0.08) (data not shown). Table 3 shows the risk
ratios associated to TP53 mutations after stratification for
BRCA1 status.
There was no significant difference in survival observed
among TP53 mutations carriers compared to non-TP53
mutations carriers, neither for the familial nor the spo-
radic cases (Log-rank test for TP53 in familial cases: p =
0.25 and log-rank test for TP53 in sporadic cases: p = 0.88)
(Table 3).
Discussion
Some studies have reported an enhanced survival for
BRCA1 carriers with ovarian cancer compared to sporadic
cases [12-14,36,37], but these studies have not taken TP53
status in the tumors in to consideration. Other studies in
which TP53 status have been included concludes that
there is no difference in survival [16].
Our results do not show an enhanced survival rate for
familial cases compared to sporadic cases, even after
adjustment for TP53 status when all age groups were
included. Further, no significant difference in survival
rates was observed between the familial cases with and
without TP53 mutations (Table 3).
These results do not support earlier observations regard-
ing the importance of the p53/BRCA1 interaction on cell
proliferation and ovarian carcinogenesis. Most penetrance
estimates and survival rates are based on studies in popu-
lations with strong founder effects, and may therefore be
biased [15-17,38]. Two Ashkenazi founder mutations
occur in BRCA1 185delAG and 5382insC (carrier frequen-
cies of 0.9% and 0.13%), with mean age at diagnosis 54
years. How the type of mutation in the BRCA1 gene affects
survival, age at diagnosis of the disease, the response to
environmental exposure causing DNA damage, and the
efficiency of DNA repair, is not clarified. Heterozygote
advantage or an increase in biological fitness conferred on
carriers of a disease causing mutation (like BRCA1?), often
a resistance to certain infections that were common in
times past, can cause an increase in allele frequency [39].
Genetic factors with impact on survival and age at onset of
disease, to after childbearing age, would be preferential.
The trend for an increased survival in favour of the early
age at onset in familial cases compared to late age at onset
in familial cases may be attributed to younger patients
having greater physical strength, less somatic mutations,
and manage illness better than older patients. On the
other hand, one might also expect this trend in sporadic
cases, which was not the case. One limitation of our study
Table 3: Hazard risk of TP53 mutations on familial and sporadic ovarian cancer cases.
# cases HR CI (95%) p-value
Familial Cases 30
TP53 no mutation 14 1 (ref)
TP53 mutation 16 1.64 0.71 – 3.78 0.25
Sporadic cases 100
TP53 no mutation 26 1 (ref)
TP53 mutation 76 0.96 0.55 – 1.66 0.88Page 5 of 8
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statistical power to detect BRCA1 effect was 76%.
Consequently, our findings should be confirmed in larger
studies. The conflicting literature on the impact of BRCA1
mutation status on ovarian cancer survival should pro-
mote additional studies from different ethnic popula-
tions, and thereby allow investigators to study whether or
not there is a survival benefit due to BRCA1 mutation, or
may be secondary to other common inherited genetic fac-
tors, which may be shared in ethnic or geographic isolated
populations.
Alterations in the TP53 gene have been shown to affect
breast cancer survival and in particular patients with
mutations in the zinc-binding domains have poor sur-
vival [40]. In sporadic ovarian carcinoma several studies
reports that no or little effect of TP53 mutations have been
seen [17,24,28], which is similar to the results reported
here. TP53 alterations are also suggested to alter ovarian
cancer survival in BRCA1 germ line patients [13,14], while
other groups concludes with a failure of BRCA1 dysfunc-
tion to alter ovarian cancer survival [16]. It should also be
noted that a considerable fraction (60–80%) of all famil-
ial BRCA1 ovarian cancers harbor TP53 mutations
[18,19,21,22]. Only a few studies have reported analysis
of TP53 mutations in relation to BRCA1 associated ovar-
ian cancer [20,41]. The present study is the first investigat-
ing somatic TP53 mutations in ovarian tumors from
carries of two distinct high penetrant BRCA1 germ-line
mutations, relating it to survival and age at diagnosis of
disease and compares it to sporadic cases. We have previ-
ously studied the distribution in age at diagnosis in
BRCA1 carriers and non-carriers as a part of a cohort
study. Three percent of Norwegian ovarian cancers are
caused by BRCA1 1675delA or 1135insA [31,42], with a
distribution similar to that found in this study (Table 1).
Further, Bjørge et al. [43] found that 87.0% of Norwegian
sporadic ovarian cancers was papillary serous adenocarci-
noma, an aggressive histo-prognostic factor.
Eigthy percent of both familial and sporadic ovarian can-
cer cases in this study were papillary serous adenocarci-
noma. Questions need to be addressed concerning the
clinical effects of mutations in the BRCA1 gene, why some
mutation carriers develop breast cancer, others develop
ovarian cancer, and some develop both. We do not know
whether the cancers occurring in mutation carriers are sig-
nificantly different from those occurring in non carriers.
The frequency of TP53 mutations in the familial cases
altering the protein was 53.3%, which is somewhat higher
than other studies of familial BRCA1 ovarian cancer (31–
50%) [18-22,24,25]. Although the number of familial
cases in this study is limited, a slightly higher frequency of
mutations was found in exon 8 and a lower frequency in
exon 5 compared to sporadic cases in the IARC database.
The same tendency has been reported by others [20].
However, a non-significant difference in TP53 mutation
frequency was observed between the familial and sporadic
cases in this study.
Of the novel mutations found in the familial cohort the
codon 205 mutation has previously been reported in sev-
eral other tumors like head and neck SCC as well as breast-
and colorectal carcinoma. The amino acid change in
codon 255 and 293 are only reported once, in oesopha-
geal SCC and bladder cancer, respectively. The silent
codon 260 mutation are reported in two different cancer
tissues; lung (SCLC) and colorectal carcinoma. Environ-
mental exposure, both external and internal, is known to
influence the spectrum of mutations. Whether hormonal
disturbance may affect the mutation rate and spectrum is
not known, but if so, it may be expected that BRCA1 car-
riers are more sensitive to such exposure.
Conclusion
Interestingly, no difference in survival was observed
between TP53 mutation carriers among the familial car-
ries or among the sporadic cases (Table 3). Further, we did
not find an overall difference in survival between familial
BRCA1 carriers and sporadic epithelial ovarian cancer
cases, even after adjustment for TP53 status. For cases
diagnosed over the age 50 there was a trend toward higher
survival for sporadic cases.
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